Displaying 1 - 3 of 3
| Active Ingredient | HYDROXYPROGESTERONE |
| Therapeutic Class | PROGESTINS |
| Indications | Amenorrhea, pre-term labour (prophylaxis). |
| Caution | Changes in appetite or weight, fluid retention, oedema, acne, chloasma (melasma), allergic skin rashes. |
| Dose Range |
Pre-term labour (prophylaxis): 250-500mg intramuscularly weekly during first half of pregnancy or longer. Amenorrhea: 375mg intramuscularly . |
| Drug Interactions | |
| Pregnancy | |
| Breast Feeding |
| Active Ingredient | MEDROXYPROGESTERONE |
| Therapeutic Class | PROGESTINS |
| Indications |
Anovulatory dysfunctional uterin e bleeding (DUB), post menopausal hormone replacement therapy, contraception, carcinoma of the endometrium. |
| Caution | Fluid retention, menstrual disorders. Use with caution in conditions which worsen fluid retention. c.f. prescribing in liver disease p. 15. |
| Dose Range |
Oral: 2.5-10mg daily for at least 10 day s p er month as HRT; daily from day s 16 or 21 of cycle for 5-10 days in anovulatory DUB. Higher p arenteral doses are required in endometrical cancer. |
| Drug Interactions | |
| Pregnancy | |
| Breast Feeding |
| Active Ingredient | NORETHISTERONE |
| Therapeutic Class | PROGESTINS |
| Indications | See Medroxy progesterone Acetate. |
| Caution | c.f. prescribing in liver disease p. 15. Contraindicated in pregnancy . Ten times more potent than medroxy progesterone. |
| Dose Range |
Dysfunctional Uterine Bleeding: 1-2 tab. Daily for 6-12 days. To prevent relapse, 1-2 tab daily from 16th-25th day of cycle, combined with oestrogen if necessary . Endometriosis: 1 tab. Daily from 5th- 25th day of cycle for 6 mth or ½ tab. Daily , continu |
| Drug Interactions | |
| Pregnancy | |
| Breast Feeding |